Compare FSUN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | DMRA |
|---|---|---|
| Founded | 1892 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2017 | 2020 |
| Metric | FSUN | DMRA |
|---|---|---|
| Price | $40.16 | $29.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $45.00 | $43.00 |
| AVG Volume (30 Days) | 238.1K | ★ 306.7K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.00 | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.34 | N/A |
| Revenue Next Year | $14.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.95 | $16.50 |
| 52 Week High | $42.34 | $34.89 |
| Indicator | FSUN | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 46.05 |
| Support Level | $39.38 | $28.16 |
| Resistance Level | $40.35 | $34.23 |
| Average True Range (ATR) | 0.75 | 1.50 |
| MACD | -0.14 | -0.25 |
| Stochastic Oscillator | 48.59 | 4.72 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.